Table 2.
Associations between ERCC1 expression and clinical characteristics in groups with or without adjuvant chemotherapy
| Characteristic | Adjuvant chemotherapy (n = 57) | No adjuvant chemotherapy (n = 36) | Total (n = 93) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| |
ERCC1 (+) (n = 34) |
ERCC1 (−) (n = 23) |
P |
ERCC1 (+) (n = 20) |
ERCC1 (−) (n = 16) |
P |
ERCC1 (+) (n = 54) |
ERCC1 (−) (n = 39) |
P |
| Sex |
|
|
0.49 |
|
|
0.19 |
|
|
0.21 |
| Men |
29 (85.3%) |
18 (78.3%) |
|
19 (95.0%) |
13 (81.3%) |
|
48 (88.9%) |
31 (79.5%) |
|
| Women |
5 (14.7%) |
5 (21.7%) |
|
1 (5.0%) |
3 (18.8%) |
|
6 (11.1%) |
8 (20.5%) |
|
| Age at operation |
|
|
0.35 |
|
|
0.24 |
|
|
0.92 |
| ≥ 65 years |
8 (23.5%) |
8 (34.8%) |
|
15 (75.0%) |
9 (56.3%) |
|
23 (42.6%) |
17 (43.6%) |
|
| < 65 years |
26 (76.5%) |
15 (65.2%) |
|
5 (25.0%) |
7 (43.8%) |
|
31 (57.4%) |
22 (56.4%) |
|
| T stage |
|
|
0.68 |
|
|
0.65 |
|
|
0.99 |
| T1-T2 |
2 (5.9%) |
2 (8.7%) |
|
9 (45.0%) |
6 (37.5%) |
|
11 (20.4%) |
8 (20.5%) |
|
| T3-T4 |
32 (94.1%) |
21 (91.3%) |
|
11 (55.0%) |
10 (62.5%) |
|
43 (79.6%) |
31 (79.5%) |
|
| N stage |
|
|
0.48 |
|
|
0.58 |
|
|
0.13 |
| Node negative |
16 (47.1%) |
13 (56.5%) |
|
16 (80.0%) |
16 (100%) |
|
32 (59.3%) |
29 (74.4%) |
|
| Node positive |
18 (52.9%) |
10 (43.5%) |
|
4 (20.0%) |
0 (0%) |
|
22 (40.7%) |
10 (25.6%) |
|
| Histologic type |
|
|
0.64 |
|
|
0.87 |
|
0.69 |
|
| Squamous differentiation |
|||||||||
| 6 (17.6%) |
3 (13.0%) |
|
1 (5.0%) |
1 (6.3%) |
|
7 (13.0%) |
4 (10.3%) |
||
| Other types |
28 (82.4%) |
20 (87.0%) |
|
19 (95.0%) |
15 (93.8%) |
|
47 (87.0%) |
35 (89.7%) |
|
| Pathologic grade* |
|
|
0.74 |
|
|
0.69 |
|
|
0.22 |
| Grade 2 |
2 (5.9%) |
5 (21.7%) |
|
2 (10.0%) |
1 (6.3%) |
|
6 4 (7.4%) |
(15.4%) |
|
| Grade 3 | 32 (94.1%) | 18 (78.3%) | 18 (90.0%) | 15 (93.8%) | 50 (92.6%) | 33 (84.6%) | |||
*1973 WHO grading.